C.R. Bard Inc. acquires SenoRx Inc. for $200 million, or $11 per share.
C.R. Bard Inc. (NYSE:BCR) closed its acquisition of SenoRx Inc. (NSDQ:SENO).
The Murray Hill, N.J.-based device conglomerate bought Irvine, Calif.-based SenoRx for about $200 million, or $11 per share.
The Hidden Administrative Tasks Draining Small Practices
Small practices play a critical role in healthcare delivery, but they cannot continue to absorb ever-increasing administrative demands without consequences.
C.R. Bard made the purchase at a 14 percent premium over SenoRx’s May 4 closing price, when the companies announced the deal. The share price also represents a 41 percent premium above the average closing price of SenoRx shares in the 90 trading days running up to the announcement, according to a press release.
SenoRx develops devices for detecting and treating breast cancer. Its products include the EnCor breast biopsy system, Gel Mark breast tissue markers and Contura balloon catheter. The company’s revenue was $55.6 million in 2009.
C.R. Bard posted first-quarter sales of $650.8 million, up 9.1 percent compared with $596.4 million during the same period last year. In December 2009, it purchased the Salt Lake City-based hemodialysis catheter business of Spire Corp. (NSDQ:SPIR).
Why Pharma Companies Should Look To Social Media For Better Patient Insight
Healthcare decision-makers, especially at pharmaceutical companies, must prioritize patient input. Data collected from social media listening is a significant step in the right direction.
The Massachusetts Medical Devices Journal is the online journal of the medical devices industry in the Commonwealth and New England, providing day-to-day coverage of the devices that save lives, the people behind them, and the burgeoning trends and developments within the industry.
This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.